Q-omics provides the consensus-scored GSTA9P profile across patient tissues and cancer cell-line models. GSTA9P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, GSTA9P is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, GSTA9P RNA expression shows 8,205 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight LUSC, LUAD, and ESCA as cancer lineages where GSTA9P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GSTA9P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GSTA9P survival associations across molecular data types. GSTA9P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GSTA9P RNA expression–survival associations across cancer types. High GSTA9P expression shows unfavorable associations in KIRP, PAAD and THCA, but favorable associations in LUSC, CESC and HNSC. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify LUSC as the clearest survival context for GSTA9P RNA expression.
This table summarizes GSTA9P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for GSTA9P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GSTA9P shows lower tumor expression in LUAD and ESCA and higher tumor expression in UCEC, LUSC, KICH and THCA. The LUAD box plot shows higher GSTA9P RNA expression in normal versus tumor tissue (log2 FC = −0.225, t-test p = .010).
This table shows molecular features associated with GSTA9P in patient tissues and cancer cell lines. In patient samples, GSTA9P shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
